A new investigation “could revolutionize“the treatment of cholangiocarcinoma (CCA), an extremely aggressive and of difficult treatment. And researchers from the Cima University of Navarra, together with the Network Biomedical Research Center in the area of Liver and Digestive Diseases (CIBEREHD), have identified a new epigenetic target that could shed light on this disease.
“Cholangiocarcinoma represents one of the greatest therapeutic challenges in oncologysince current treatments offer limited effectiveness. The research team has identified a promising therapeutic target, the enzyme PRMT5which plays a crucial role in the progression of CCA. This discovery opens new possibilities for the creation of more effective treatments,” he indicated. CYBER in a statement.
To take into account
Among other things, the study has revealed that enzine PRMT5whose levels are high in patients with CCA and which is related to a more serious disease. advancedcan be blocked through medications already approved for other types of tumors.
And that, through these, the growth of tumor cells has been stoppedreported the principal investigator of CIBEREHD, leader of the research and co-director of the Cima Solid Tumors Program, Matias Avila.
More details
As if that were not enough, experts have also observed that the combination of these medications and conventional chemotherapy “significantly increased the antitumor effect,” showing “great therapeutic potential,” as validated in CCA models of mouse.
Without a doubt, these discoveries could make way -both in the short and long term- to new clinical trials that, in turn, could significantly improve the treatment of this disease.
The results of the research, in which specialists from Italy, Poland and Germanyhave been published in the British magazine ‘Gut‘, and they contribute “a new hope to combat a disease whose incidence has been increasing in recent years“.
#Revolutionary #finding #type #liver #cancer
